CHRS Q1 2020 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$116M+213.2% YoY

Gross Profit

$109M94.1% margin

Operating Income

$41M35.2% margin

Net Income

$36M30.6% margin

EPS (Diluted)

$0.48

QoQ Revenue Growth

-6.2%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$12M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$467M

Total Liabilities

$309M

Stockholders' Equity

$157M

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$116M	$37M	+213.2%
Gross Profit	$109M	$35M	+213.5%
Operating Income	$41M	-$17M	+346.2%
Net Income	$36M	-$20M	+277.8%